Orchid Pharma Limited
Orchid Pharma Limited (ORCHPHARMA.NS) Stock Forecast & Price Predictions
Get the latest Orchid Pharma Limited (ORCHPHARMA.NS) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.
Model Information
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMonthly Forecast
Quarterly Forecast
Yearly Forecast
3 Years Forecast
5 Years Forecast
7 Years Forecast
Orchid Pharma Limited Stock Forecast Summary
Orchid Pharma Limited (ORCHPHARMA.NS) stock is currently priced at $546.60. Based on Meyka AI predictions, the short-term outlook is bullish, with momentum pointing higher. The 1-month projection suggests a move toward $568.31.
In the long term, ORCHPHARMA.NS shows a bullish trend. The 2027 forecast points to $1080.69 (97.71% change), while the 2031 forecast suggests $1447.80 (164.87% change). Looking 7 years ahead, projections estimate the stock could trade near $1503.30, a 175.03% change from today’s price.
Bullish
Bullish
Bullish
This mix indicates that Orchid Pharma Limited stock is expected to rise steadily over the coming years.
Investment Calculator
Estimate your potential returns on ORCHPHARMA.NS using our advanced Investment Calculator with AI-driven price forecasts. Enter your investment amount and select a target date to view expected results, including estimated profit, loss, and ROI performance.
Based on your investment of ₹1,000.00 in Orchid Pharma Limited and holding until April 15th, 2027, you could face a potential +₹977.12 profit, reflecting a +97.7% ROI over the next 365 days. These projections help you better understand short-term market movements.
$Shares Bought
1.8295
@ ₹546.60/share
~Forecast Price
₹1,080.69
1-year AI forecast
$Est. Portfolio Value
₹1,977.12
+₹977.12 profit
%ROI
+97.7%
return on investment
Orchid Pharma Limited yearly Price Forecast Chart
Explore the yearly forecast chart for ORCHPHARMA.NS, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate Orchid Pharma Limited over different timeframes.
No forecast data available
No prediction data found for this time period.
Forecasting data is not available for ORCHPHARMA.NSForecasting details for ORCHPHARMA.NS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.Orchid Pharma Limited Stock Forecast 2026
The forecast for Orchid Pharma Limited (ORCHPHARMA.NS) in 2026 suggests a price of $1080.69, representing a 97.71% move from today’s price.
Average Target: $1080.69
Market Outlook: bullish based on current trend indicators.
Key Drivers in 2026:- Earnings growth projections.
- Competitive performance in the Healthcare.
- Macroeconomic factors such as interest rates and inflation.
Orchid Pharma Limited Stock Forecast 2030
By 2030, Meyka AI projects ORCHPHARMA.NS could trade near $1447.80, showing a potential 164.87% compared to current levels.
Average Target: $1447.80
Market Outlook: bullish.
What could influence the 2030 forecast:- Technological innovation and product cycles.
- Expansion into global markets.
- Long-term investor sentiment toward Orchid Pharma Limited.
Orchid Pharma Limited 7-Year Stock Forecast (2032–2033)
Looking 7 years ahead, the long-term forecast for ORCHPHARMA.NS points to a price around $1503.30, which is a projected 175.03% move from today’s level.
Average Target: $1503.30
Outlook: bullish, depending on macroeconomic conditions and sector growth.
Long-Term Drivers:- Global economic expansion or contraction.
- Regulatory and policy environment.
- Orchid Pharma Limited’s ability to maintain market leadership.